コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ity issues and was considered as a backup to vilanterol.
3 asone furoate, HR 0.91 [0.77-1.08]; p=0.284; vilanterol, 0.96 [0.81-1.14]; p=0.655), and therefore se
4 le therapy (fluticasone furoate/umeclidinium/vilanterol 100 mug/62.5 mug/25 mug; ELLIPTA inhaler) wit
5 ong-acting beta2-agonist fluticasone furoate/vilanterol 100/25 mug or placebo (7-day minimum washout)
6 , 2011 and Oct 17, 2011) in which once a day vilanterol 25 mug was compared with 25 mug vilanterol pl
7 aled placebo, fluticasone furoate (100 mug), vilanterol (25 mug), or the combination of fluticasone f
9 te and salmeterol or fluticasone furoate and vilanterol); a control arm (not given inhaled fluticason
10 novel once-daily beta2-agonists (olodaterol, vilanterol, abediterol) are under development, mainly in
11 l reduced exacerbations by 29% compared with vilanterol alone (mean 0.91 vs 1.28 exacerbations per pa
12 ion and Medication Ordering System to 25 mug vilanterol alone or 25 mug vilanterol combined with eith
13 icasone furoate and vilanterol compared with vilanterol alone were not associated with eosinophil cou
15 casone furoate and vilanterol, compared with vilanterol alone, were 24% in patients with baseline eos
18 Indacaterol/glycopyrronium, umeclidinium/vilanterol, and olodaterol/tiotropium FDCs have been app
19 fluticasone furoate at a dose of 100 mug and vilanterol at a dose of 25 mug (the fluticasone furoate-
20 System to 25 mug vilanterol alone or 25 mug vilanterol combined with either 50 mug, 100 mug, or 200
21 sk of pneumonia with fluticasone furoate and vilanterol compared with vilanterol alone were not assoc
22 ients initiated with fluticasone furoate and vilanterol, compared with 2.8 points in the usual care g
23 n exacerbations with fluticasone furoate and vilanterol, compared with vilanterol alone, were 24% in
24 e furoate, and the long-acting beta agonist, vilanterol could improve survival compared with placebo
25 risk, treatment with fluticasone furoate and vilanterol did not affect mortality or cardiovascular ou
26 erence 8 mL per year [95% CI 1-14]), but not vilanterol (difference -2 mL per year [95% CI -8 to 5]).
27 d between the 200/25 mug fluticasone furoate/vilanterol group and the vilanterol only group (mean 0.9
28 [71%] of 1373 in the fluticasone furoate and vilanterol group vs 784 [56%] of 1399 in the usual care
29 the fluticasone furoate group, and 4% in the vilanterol group) or adverse cardiac events (17% in the
30 at a dose of 25 mug (the fluticasone furoate-vilanterol group) or to usual care (the usual-care group
31 he fluticasone furoate group, and 17% in the vilanterol group) were noted in the treatment groups.
32 n the fluticasone furoate group, 4118 in the vilanterol group, and 4121 in the combination group.
34 umonia were noted in the fluticasone furoate/vilanterol groups compared with none in the vilanterol o
35 ations were noted in all fluticasone furoate/vilanterol groups than in the vilanterol only group (0.0
36 ations were noted in all fluticasone furoate/vilanterol groups than in the vilanterol only group (p=0
37 o usual care, 602 to fluticasone furoate and vilanterol) had a baseline ACT score greater than or equ
38 regimen of combined fluticasone furoate and vilanterol improved asthma control without increasing th
41 casone furoate/vilanterol groups than in the vilanterol only group (0.0141 for the 50 mug group, <0.0
42 fluticasone furoate/vilanterol group and the vilanterol only group (mean 0.90 events vs 1.05 events p
43 casone furoate/vilanterol groups than in the vilanterol only group (p=0.0398 for the 50 mug group, 0.
45 g or 200 mug fluticasone furoate with 25 mug vilanterol or optimised usual care and followed up for 1
46 y vilanterol 25 mug was compared with 25 mug vilanterol plus 50 mug, 100 mug, or 200 mug fluticasone
47 led corticosteroids, fluticasone furoate and vilanterol reduced exacerbations by 29% compared with vi
50 iated treatment with fluticasone furoate and vilanterol than for those on usual care (977 [71%] of 13
54 (FF) and long-acting beta(2) -agonist (LABA) vilanterol (VI) on early and late asthmatic responses (E
55 icacy and safety of umeclidinium (UMEC) plus vilanterol (VI) with tiotropium (TIO) monotherapy, UMEC
56 placebo, fluticasone furoate (FF; 100 mug), vilanterol (VI; 25 mug), or the combination of FF/VI was
58 regimen of combined fluticasone furoate and vilanterol was associated with a lower rate of exacerbat
59 We hypothesised that fluticasone furoate and vilanterol would prevent more exacerbations than would v
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。